PUBLICATION

Spironolactone affects cardiovascular and craniofacial development in zebrafish embryos (Danio rerio)

Authors
Petty, H.J., Barrett, J.E., Kosmowski, E.G., Amos, D.S., Ryan, S.M., Jones, L.D., Lassiter, C.S.
ID
ZDB-PUB-220316-5
Date
2022
Source
Environmental Toxicology and Pharmacology   92: 103848 (Journal)
Registered Authors
Lassiter, Christopher S.
Keywords
cardiovascular, cartilage, craniofacial, spironolactone, zebrafish
MeSH Terms
  • Dihydrotachysterol
  • Humans
  • Zebrafish*
  • Diuretics
  • Embryonic Development
  • Spironolactone*/pharmacology
  • Animals
(all 7)
PubMed
35288337 Full text @ Environ. Toxicol. Pharmacol.
Abstract
Spironolactone, a potassium-sparing diuretic and aldosterone antagonist, is a mineralocorticoid hormone commonly prescribed to patients suffering from heart failure, hirsutism, dermatological afflictions, and hypertension. Interestingly, relatively little work has been done on the development of vertebrate embryos after exposure to this compound. Here, we treat zebrafish embryos with spironolactone at 10-6M, 10-7M, or 10-8M, and observe them after three to seven days of exposure. While no effect was observed in mortality, we did detect differences in cardiovascular development at 3 dpf and craniofacial development at 5 dpf. At 10-6M, smaller atria, ventricles, and blood vessels were observed. The highest concentrations also caused a longer ceratohyal/Meckel's distance, longer palatoquadrate, and smaller angles between the palatoquadrate and both the ceratohyal and Meckel's. Further research of spironolactone's effects on embryonic development could lead to a better understanding of the compound resulting in improved public and environmental health.
Genes / Markers
Figures
No images available
Show all Figures
Expression
Phenotype
Fish Conditions Stage Phenotype Figure
ABchemical treatment by environment: spironolactoneProtruding-mouth
ABchemical treatment by environment: spironolactoneDay 5
ABchemical treatment by environment: spironolactoneDay 5
ABchemical treatment by environment: spironolactoneDay 5
is5Tg/is5Tgchemical treatment by environment: spironolactoneProtruding-mouth
is5Tg/is5Tgchemical treatment by environment: spironolactoneProtruding-mouth
s878Tg/s878Tgchemical treatment by environment: spironolactoneProtruding-mouth
s878Tg/s878Tgchemical treatment by environment: spironolactoneProtruding-mouth
s878Tg/s878Tgchemical treatment by environment: spironolactoneProtruding-mouth
1 - 9 of 9
Show
Mutations / Transgenics
Allele Construct Type Affected Genomic Region
is5TgTransgenic Insertion
    s878TgTransgenic Insertion
      1 - 2 of 2
      Show
      Human Disease / Model
      No data available
      Sequence Targeting Reagents
      No data available
      Fish
      Fish
      AB
      is5Tg/is5Tg
      s878Tg/s878Tg
      1 - 3 of 3
      Show
      Antibodies
      Orthology
      Engineered Foreign Genes
      Marker Marker Type Name
      GCaMPEFGGCaMP
      mCherryEFGmCherry
      1 - 2 of 2
      Show
      Mapping
      Your Input Welcome
      We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
      Citation
      Petty, H.J., Barrett, J.E., Kosmowski, E.G., Amos, D.S., Ryan, S.M., Jones, L.D., Lassiter, C.S. (2022) Spironolactone affects cardiovascular and craniofacial development in zebrafish embryos (Danio rerio). Environmental Toxicology and Pharmacology. 92:103848.